The U.S. Dental Membrane and Bone Graft Substitutes Market size is anticipated to grow at a CAGR of 8.6% with USD 550 Mn in 2026 and is expected to reach USD 980 Mn in 2033. The market is growing with the rising dental implant procedures, increasing periodontal disease burden, growing use of guided bone regeneration, and higher demand for socket preservation and ridge augmentation. According to the CDC, nearly 42% of U.S. adults aged 30 years and older have periodontitis, while severe periodontitis affects about 8% of adults, supporting continued demand for bone regeneration solutions.
On the basis of product type, the bone graft substitutes segment accounts for the largest U.S. Dental Membrane and Bone Graft Substitutes Market share of 62.4% in 2026. The growth of the segment is mainly driven by the strong clinical need to rebuild alveolar bone after tooth extraction, periodontitis, and implant-site preparation.
In addition, the NIDCR reported that the U.S. seniors aged 65 years and older had an average of 21 remaining teeth, while about 15% had no remaining natural teeth. This highlights the need for ridge preservation and implant-related reconstruction.
In February 2025, LifeNet Health launched OraGen, the first viable dental bone allograft using cryopreserved corticocancellous bone with osteogenic, osteoconductive and osteoinductive properties. The product is available in the U.S. through Salvin Dental Specialties and is used in sinus and ridge augmentation procedures.

To learn more about this report, Request Free Sample
On the basis of material, the collagen segment accounts for the largest U.S. Dental Membrane and Bone Graft Substitutes Market share of 32.5% in 2026. The segment’s growth is owing to the fact that they are resorbable, biocompatible, and suitable for guided bone regeneration and guided tissue regeneration.
ClinicalTrials.gov also listed a May 2026 study evaluating whether adding a resorbable collagen membrane to an anorganic bone-collagen composite graft improves ridge preservation, showing active clinical interest in collagen membrane use.
In February 2024, BioHorizons Camlog launched Striate+, a collagen membrane developed by Orthocell for guided bone and tissue regeneration. The porcine-derived, biocompatible membrane supports implant dentistry through handling, bilayer osteoconductive design, and physiological resorption within 26 weeks, reducing reintervention needs.
On the basis of application, the socket preservation segment is projected to secure the largest share of 28.6% in 2026. The segment’s growth is owing to the high clinical need to maintain alveolar ridge volume immediately after tooth extraction, supporting future implant placement and restorative dentistry.
U.S. disease burden continues to create a steady pool of extraction-risk patients. CDC’s 2024 Oral Health Surveillance Report reported untreated decay in permanent teeth among 20.5% of dentate adults aged 20–64.
In March 2026, FDA granted 510(k) substantial-equivalence clearance to Hudens Bio’s BONTREE PLUS, a synthetic HA/OCP bone graft material indicated for extraction sites, ridge augmentation, sinus lifts, and periodontal defects in the commercial U.S. market.
On the basis of end user, the dental clinics segment is expected to occupy the highest share of 52.3% in 2026. The segment’s growth is due to their central role in implant placement, socket preservation, ridge augmentation, and guided bone regeneration procedures.
Clinics benefit from high patient flow for routine and surgical dentistry. The CDC reported that 65.5% of U.S. adults had a dental exam or cleaning in the past year in 2023.
The U.S. market is seeing strong innovation in collagen-based dental membranes, particularly in handling strength, hydrated stability, tensile resistance, and adaptation to ridge contour. These features are important because regenerative dental procedures require barrier membranes to maintain space, prevent soft tissue ingrowth, and support the bone formation during guided bone regeneration.
Dentsply Sirona’s regenerative portfolio, for example includes bone graft materials, resorbable and non-resorbable membranes, and instruments under its Symbios line, thereby reflecting the shift toward integrated regenerative workflows.
In October 2025, Geistlich launched Geistlich Bio-Gide Forte, an advanced resorbable collagen membrane based on proven Bio-Gide technology, in North America. Such product upgrades are expected to increase the adoption of premium collagen membranes in hospitals, oral surgery centers, as well as dental implant practices.
Next-generation biomaterials are reshaping the Dental Membrane and Bone Graft Substitutes Market by improving socket preservation, guided bone regeneration, and implant-site preparation with resorbable, osteoconductive, and membrane-supported materials.
The regulatory activity also supports biomaterial innovation. In February 2025, FDA determined Shenzhen Dazhou Medical Technology’s Synthetic Bone Graft Particulate substantially equivalent under 510(k). The device is a sterile, absorbable 45S5 bioactive-glass particulate, sized 0.5–1 mm. It is intended to augment alveolar bone in tooth-extraction sockets and progressively resorb as new bone forms.
This speeds up the adoption of cutting edge synthetic alternatives across dental clinics as well as hospitals for the U.S. commercial use.
|
Current Event |
Description and its Impact |
|
FDA guidance on animal studies for dental bone grafting material devices, August 2025 |
|
|
UnitedHealthcare Dental Clinical Policy update on dental barrier membranes, May 2026 |
|
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Some of the major key players in U.S. Dental Membrane and Bone Graft Substitutes Market are Institut Straumann AG, Nobel Biocare Services AG, Geistlich Pharma AG, Zimmer Biomet Holdings, Inc., Dentsply Sirona, Inc., BioHorizons, Inc., NovaBone Products, LLC, Collagen Matrix, Inc., Maxigen Biotech, Inc., Osteogenics Biomedical, Medtronic, OUSIA
| Report Coverage | Details | ||
|---|---|---|---|
| Base Year: | 2025 | Market Size in 2026: | USD 550 Mn |
| Historical Data for: | 2020 To 2024 | Forecast Period: | 2026 To 2033 |
| Forecast Period 2026 to 2033 CAGR: | 8.6% | 2033 Value Projection: | USD 980 Mn |
| Segments covered: |
|
||
| Companies covered: |
Institut Straumann AG, Nobel Biocare Services AG, Geistlich Pharma AG, Zimmer Biomet Holdings, Inc., Dentsply Sirona, Inc., BioHorizons, Inc., NovaBone Products, LLC, Collagen Matrix, Inc., Maxigen Biotech, Inc., Osteogenics Biomedical, Medtronic, OUSIA |
||
| Growth Drivers: |
|
||
| Restraints & Challenges: |
|
||
Uncover macros and micros vetted on 75+ parameters: Get instant access to report
Share
Share
Manisha Vibhute is a consultant with over 5 years of experience in market research and consulting. With a strong understanding of market dynamics, Manisha assists clients in developing effective market access strategies. She helps medical device companies navigate pricing, reimbursement, and regulatory pathways to ensure successful product launches.
Joining thousands of companies around the world committed to making the Excellent Business Solutions.
View All Our Clients